Dr Jane Osbourn

Vice-President R&D, MedImmune

Jane Osbourn PhD is VP Research and Development and Site Leader for MedImmune in Cambridge, having joined MedImmune (formerly Cambridge Antibody Technology (CAT) and now the global biologics research and development arm of AstraZeneca) in 1993.

An expert in antibody engineering, she originated several key publications and patents, and has also made a significant contribution to the discovery and development of marketed drugs (Humira and Benlysta) and more than 40 clinical candidates. Jane is Chair of the Board of Directors of the BioIndustry Association, a Director of Babraham Bioscience Technologies, a Director of Cambridge Enterprise and has presented at a number of parliamentary Select Committees.